Article published in Urologia Polska 1999/52/2.

authors

Romuald Zdrojowy: Katedra i Klinika Urologii AM, Wrocław
Kierownik Kliniki: prof. dr hab. n. med. Jerzy Lorenz

[1] Bruwer, G., Heyns, C. F., Allen, F. J.: Influence of local tumour stage and
grade on reliability of serum Prostate-specific antigen in predicting Skeletal metastases
in patients with adenocarcinoma of the prostate. Eur. Urol. 1999,35, 223-227.
[2] Chybowski, F. M., Larson-Keller, J. }., Bergstralh, E. ]., Oesterling,
J. E.: Predicting radionuclide bone scan findings in patients with newly diagnosed,
untreated prostate cancer: Prostate-specific antigen is superior to all other clinical
parameters. J. Urol., 1991,145, 313-318.
[3] 0'Dowd, G. J., Veltri, R. W., Orozco, R., Miller, M. C, Oesterling,
J. E.: Update on the appropriate staging evaluation for newly diagnosed prostate
cancer. J. Urol. 1997,158, 687-698.
[4] Oefelein, M. G., Smith; N., Carter, M., Dalton, D., Schaeffer, A.: The
incidence of prostate cancer progression with undetectable serum prostate specific
antigen in a series of 394 radical prostatectomies. J. Urol. 1995,154, 2128-2131.
[5] Oesterling, J. E.: Using PSA to eliminate the staging radionuclide bone scan.
Significant economic implications. Urol. Clin. N. Amer. 1993, 20, 705-711.